The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care.
Adoptive immunotherapy-in particular, T-cell therapy-has recently emerged as a useful strategy with the potential to overcome many of the limitations of antiviral drugs for the treatment of viral complications after hematopietic stem cell transplantation. In this review, we briefly summarize the current methods for virus-specific T-cell isolation or selection and we report results from clinical trials that have used these techniques, focusing specifically on the strategies aimed to broaden the application of this technology.
Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, Turin, Italy.
Francesco
F
Saglio
Program for Cell Enhancement and Technologies for Immunotherapy, Sheikh Zayed Institute for Pediatric Surgical Innovation, and Center for Cancer and Immunology Research, Children's National Medical Health System, Washington, DC, USA.
Patrick J
PJ
Hanley
Program for Cell Enhancement and Technologies for Immunotherapy, Sheikh Zayed Institute for Pediatric Surgical Innovation, and Center for Cancer and Immunology Research, Children's National Medical Health System, Washington, DC, USA. Electronic address: cbollard@childrensnational.org.
Catherine M
CM
Bollard
D000818:Animals; D000956:Antigens, Viral / Q000276:immunology; D002986:Clinical Trials as Topic; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods* / Q000639:trends; D011183:Postoperative Complications / Q000276:immunology* / Q000517:prevention & control; D059039:Standard of Care; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation; D014184:Transplantation, Homologous; D014777:Virus Diseases / Q000276:immunology* / Q000517:prevention & control
D000956:Antigens, Viral
T cell; immunotherapy; stem cell transplantation; virus